Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on December 11, 2014, covering events occurring on December 9 and December 10, 2014. The filing addresses significant intellectual property events regarding the company's core products, Trokendi XR and Oxtellar XR.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and regulatory events rather than financial performance data.
Material Changes and Events
- Paragraph IV Notice from Par Pharmaceutical: On December 9, 2014, Supernus received notice that Par Pharmaceutical filed an Abbreviated New Drug Application (ANDA) for topiramate extended-release capsules. This product is protected by five issued patents expiring no earlier than 2027.
- Paragraph IV Notice from TWi Pharmaceuticals: On December 10, 2014, Supernus received notice that TWi Pharmaceuticals filed an ANDA for oxcarbazepine extended-release tablets. This product is protected by four issued patents expiring no earlier than 2027.
Management Commentary and Outlook
Management stated that it is currently reviewing the details of both Notice Letters. The company intends to vigorously enforce its intellectual property rights relating to both Trokendi XR and Oxtellar XR. No specific financial guidance or outlook was provided in this filing.
Investor Verification Checklist
- Verify the specific patent numbers and expiration dates for Trokendi XR and Oxtellar XR to assess the duration of market exclusivity.
- Monitor subsequent litigation filings or settlements resulting from the Paragraph IV notices issued by Par and TWi Pharmaceuticals.
- Review the attached press releases (Exhibits 99.1 and 99.2) for additional details on the generic competitors' proposed launch dates.
- Assess the potential impact of generic competition on future revenue projections for the company's topiramate and oxcarbazepine products.